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ABSTRACT  
 
Nasopharyngeal carcinoma (NPC) is one of the most common malignancies in certain 
areas of Southern China, Southeastern Asia and Northern Africa. Currently, evaluation 
of NPC prognosis is mainly based on the tumor-node-metastasis (TNM) staging 
system. However, NPC patients with the same clinical stage often present different 
clinical courses, suggesting that the TNM staging is insufficient to predict prognosis of 
this disease. Therefore, it is important to find molecular biomarkers, which can help 
clinicians to identify NPC patients with worse prognosis and develop therapeutic 
interventions in NPC patients.  
This thesis presents the identification and investigation of mechanism of several 
novel markers in NPC. In the first paper, Caveolin-1 (Cav-1), a major structural 
component of caveolae, and CD147 (also known as extracellular matrix 
metalloproteinase inducer, EMMPRIN), a glycoprotein, were found to be 
overexpressed in NPC. Both Cav-1 and CD147 expression levels correlated 
significantly with metastasis and poor prognosis of NPC patients. Further studies 
revealed that Cav-1 and CD147 enhance NPC cell migration, which is associated with 
MMP-3 and MMP-11 (active) secretion.  
The role of microRNA-155 (miR-155) is associated with oncogenesis of several 
human tumors. In the second paper, miR-155 was found to be upregulated in NPC cell 
lines and clinical samples. EBV encoded LMP1 and LMP2A could further enhance the 
expression of miR-155 in NPC CNE1 and TW03 cells. JMJD1A was identified as a 
direct target of miR-155 in NPC. Downregulation of JMJD1A was significantly 
correlated with N stage of the TNM classification, a lower five-year survival rate, and a 
lower five-year disease-free survival rate of NPC patients.  
Spleen tyrosine kinase (Syk) is a nonreceptor tyrosine kinase and often aberrantly 
expressed in human cancers. In the third paper, high expression of Syk was detected in 
24% of NPC cases. High expression of Syk, resulted partly from LMP2A expression in 
NPC, is associated with tumor recurrence and poor prognosis of NPC patients.  
Human chromosome 3 (Chr. 3) contains clusters of tumor suppressor genes (TSGs) 
involved in many cancer types. In the fourth paper, using Not I Chr. 3 microarray, ten 
candidate TSGs were found in NPC. Among them, the CpG island in the promoter 
region of Wingless-type Mouse mammary tumor virus integration site family, member 
7A (WNT7a) and the intron 1 region of Integrin α9 (ITGA9) were confirmed to be 
hypermethylated in NPC by bisulfite sequencing and methylation specific PCR. 
Demethylating agent 5-aza-2′-deoxycytidine (5-aza-CdR) treatment could restore the 
expression of WNT7a and ITGA9 in NPC cell lines. Furthermore, WNT7a and ITGA9 
were downregulated in NPC clinical samples. As both proteins execute significant 
functions related to the tumor cell biology, the potential of WNT7a and ITGA9 as 
diagnosis or therapeutic targets for NPC should be considered. 
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1 INTRODUCTION 
 
1.1 GENERNAL CHARACTERISTICS OF NPC 
 
1.1.1 Anatomy and histopathology 
Nasopharyngeal carcinoma (NPC) is a tumor arising from the mucosal epithelium 
covering the nasopharyngeal surface, most often within the lateral nasopharyngeal 
recess or fossa of Rosenmüller (the space behind the nose). The histological 
classification system of the World Health Organization (WHO), which was most 
recently revised in 1991, defines NPC as either keratinizing squamous cell carcinoma 
(Type 1) or non-keratinizing carcinoma (Type 2) ; the latter is further subdivided into 
non-keratinizing differentiated carcinoma (Type 2a) and non-keratinizing 
undifferentiated carcinoma (Type 2b) (Table 1) 1. The most common form, 
non-keratinizing undifferentiated carcinoma, shows a close to 100% prevalence of 
Epstein-Barr virus (EBV) in the tumor cells2.  
 
Table 1 Histological subtypes of NPC classified by World Health Organization 
Histological subtypes Characteristics WHO 
Types 
Keratinizing squamous cell carcinoma Highly differentiated, epithelial 
growth patterns, keratin filaments 
Type 1 (I) 
Non-keratinizing 
differentiated carcinoma 
Retaining epithelial cell shape 
and growth pattern 
Type 2a (II)
Non-keratinizing 
carcinoma Non-keratinizing 
undifferentiated carcinoma 
Lack of distinctive epithelial 
growth pattern 
Type 2b 
(III) 
 
1.1.2 Epidemiology and etiology 
NPC is an uncommon disease in most countries of the world, and its age-adjusted 
incidence for male and female is less than one per 100,000 persons 3. However NPC is 
one of the most common malignancies in certain areas of Southern China, Southeastern 
Asia and Northern Africa 4-5. The highest incidence of 25-40 per 100,000 persons was 
reported in the Sihui area of Guangdong province, Southern China6. The incidence rate 
among Chinese people born in North America is lower than in those born in Southern 
China, but still remains considerable higher than the local7-8. These findings suggest 
that genetic, ethnic and environmental factors play a role in the etiology of NPC. 
Familial NPC has been linked to susceptibility loci on chromosome 3p 219, 4p15.1-q12 
10and 5p 1311. Epstein-Barr virus (EBV) infection has been verified to be strongly 
associated with NPC 12-13. Moreover, consumption of salted fish and other preserved 
foods containing volatile nitrosamines, especially during childhood, is important 
carcinogenic factor for NPC 14-15. 
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1.1.3 Epstein-Barr virus and NPC 
EBV is a prototype gamma herpes virus which infects more than 90% of the world’s 
adult population16. Humans are the only natural host for EBV. Primary infection with 
EBV normally occurs in early childhood and is usually asymptomatic in most countries. 
However, in some individuals, EBV is implicated in the pathogenesis of several human 
malignancies including Burkitt’s lymphoma 17, Hodgkin’s lymphoma 18, gastric 
carcinoma 19 and NPC20. EBV infection in these tumors is characterized by the 
expression of viral genes expressed during latent infection, in particular, Epstein-Barr 
virus nuclear antigen 1 (EBNA1), Latent membrane protein 1 (LMP1), Latent 
membrane protein 2 (LMP2), BamHI-A rightward frame 1 (BARF1), BamHI-A 
leftward frame 1 (BALF1) and Epstein-Barr virus -encoded small RNAs (EBERs) 21-24 
(Table 2).  
 
Table 2 Expression of EBV latent genes in human diseases 
Latency types EBV genes expressed Disease associated 
Type I EBNA1, EBERs Burkitt’s lymphoma 
Type II EBNA1, LMP1, LMP2, 
EBERs, BARF1 
NPC, Hodgkin’s disease, periphpheral T cell 
lymphoma 
Type III EBNA1, EBNA2, EBNA3, 
LMP1, LMP2, EBERs 
lymhoproliferative disease, X-linked 
lymphoproliferative disease, infectious 
mononucleosis 
 
LMP1 and LMP2A are not expressed at a significant level in all NPCs, and the level of 
expression varies in different studies depending on material and methods used for 
detection. LMP1, which was reported to be expressed in as much as approximately 65% 
of NPC patients25, is the first EBV latent gene found to be able to transform cell lines 
and alter the phenotype of cells due to its oncogenic potential 26. In human epithelial 
cells, LMP1 alters many functional properties that are involved in tumor progression 
and invasion 27. LMP2A, which is expressed in around 45% of NPC patients28, was 
reported to induce primary epithelial cell migration and invasion 29. More importantly, 
Guasparri et al 30 supported that EBV LMP2A protein could affect LMP1-mediated 
Nuclear factor kappa B (NF-kB) signaling and survival of lymphoma cells. LMP1 and 
LMP2A may partly affect the same pathway, also including transcriptional regulation of 
miRNAs. Moreover, BARF131-33 and BALF134 have been found to be expressed in 
NPC biopsies, suggesting that they play a role in the pathogenesis of NPC. EBERs are 
the most abundant EBV viral transcripts and are used to detect EBV-infected cells in 
tissues by in situ hybridization. EBERs could contribute to oncogenesis by modulating 
innate immunity in patients with NPC32 
 
1.1.4 Clinical pathological characteristic and TNM staging  
NPC has a dominant clinico-pathological behavior of loco-regional recurrence and 
metastasis, which differs from that of other types of head and neck cancers35. Currently, 
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tumor-node-metastasis (TNM) staging of NPC is based on clinical and radiologic 
examination. There are various ways of classifying NPC. At present, the American 
Joint Committee on Cancer Staging and End Result Reporting / International Union 
Against Cancer (AJC/UICC) system is preferred in Europe and America36. The Chinese 
NPC staging system of 1992 (Sidebar 1) has incorporated prognostic significance, 
and according to this staging criteria, the 5-year survival rates of NPC patients in China 
for stages I, II, III and IV are 89.7%, 75.9%, 51.3%, and 22.2%, respectively37. The 
Chinese 1992 NPC staging system is considered satisfactory and has been widely used 
in China 37-39. 
 
 
Sidebar 1 The characteristics of the 1992 NPC staging system 
The staging system is characterized according to the following model: T, primary tumor: T1, 
limited to the nasopharynx; T2, involvement of the nasal cavity, oropharynx, soft palatine, 
anterior cervical vertebrae soft tissue, and parapharyngeal space extension before the SO line 
(the SO line is between the styloid process and the midpoint on the posterior edge of the great 
occipital foramen);T3, extension over the SO line, involvement of the anterior or posterior 
cranial nerves alone, the base of the skull, the pterygoprocess zone, and the pterygopalatine 
fossa; T4, involvement of both anterior and posterior cranial nerves, parabasal sinus, cavernous 
sinus, orbit, infratemporal fossa, and direct invasion of the first or second cervical vertebrae; N, 
regional lymph node involvement: N0, no enlarged lymph nodes; N1, greatest dimension of 
upper neck lymph node <4 cm, movable; N2, lower neck lymph node or greatest lymph node 
dimension between 4 and 7 cm; N3, supraclavicular lymph node, lymph node greatest dimension 
>7 cm, fixed, or skin infiltration (the border between the upper neck and the lower neck is the 
inferior margin of the cricoid cartilage); M, distant metastasis: M0, absence of distant metastasis; 
M1, presence of distant metastasis; staging: Stage I, T1N0M0; Stage II, T2N0-N1M0, 
T0-T2N1M0; Stage III, T3N0-N2M0, T0-T3N2M0; Stage IVa, T4N0-N3M0, T0-T4N3M0; 
Stage IVb, M1. 
 
1.1.5 Treatment and prognosis 
NPC is a relatively radiosensitive tumor and therefore radiotherapy remains the 
standard treatment for almost all NPC patients. The fields for targeting of radiotherapy 
to the primary tumor and the surrounding anatomical structures at risk of tumor 
invasion were defined clinically by radiographic imaging. Although more than 70% 
overall survival rates can be expected for stages I and II, treatment outcomes are 
unsatisfactory for advanced-stage NPC when radiotherapy is offered alone 40-43. 
Utilization of radiochemotherapy, which is combined modality therapy using 
chemotherapy and radiotherapy, is an important strategy for improving tumor control of 
advanced NPC to achieve improvements in survival 44-50. Although NPC is 
radiosensitive, the average five-year survival rate remains between 50-60%. Regional 
lymph node and distant metastasis and loco-regional recurrence are the two major 
reasons resulting in failure of treatment for this cancer39, 51. 
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1.2 HALLMARKS OF NPC 
 
Inspired by the seminal reviews by Douglas Hanahan and Robert A. Weinberg in 2000 
and 2011 describing general features of all cancers52-53, we have undertaken to describe 
the tumor biology of NPC following their suggested hallmarks.  
 
1.2.1 Sustaining proliferative signaling 
Cancer cells can acquire the capability to sustain proliferative signaling through 
numerable different routes. High expression of growth factor ligands themselves, 
elevating the levels of receptor proteins displayed at the cancer cell surface and 
structural alterations in receptor molecules could provide cancer cells with signals 
sustaining proliferation (Figure 1) 53. Epidermal growth factor receptor (EGFR), which 
could be induced by LMP1 54, was overexpressed in NPC 55 and could stimulate cell 
proliferation. Moreover, Met proto-oncogene (c-Met)56, Insulin-like growth factor-1 
receptor (IGF-1R)57, Teratocarcinoma-derived growth factor 1 (TDGF1, also named 
cripto-1) 58 are capable of transmitting mitogenic signals to the NPC cells.  
 
 
Figure 1 Growth-control pathway in normal cells and subversion of proliferative signaling in 
cancer cells.  
 
1.2.2 Evading growth suppressors 
Tumor suppressor gene (TSG) could negatively regulate cell proliferation, namely 
operate in various ways to limit cell growth and proliferation (Figure 2). In cancer cells, 
TSGs are usually silenced by genetic alteration (mutation and deletion)59 or epigenetic 
alteration (methylation and histone modification)60. MicroRNA let-761, miR-26a62 and 
miR-21863 could suppress NPC cell proliferation and cell growth through 
downregulating c-Myc, EZH2 and survivin respectively, and their expression was 
downregulated in NPC. Several TSGs, such as Ras association (RalGDS/AF-6) domain 
family member 1 (RASSF1 or RASSF1A) 64, The Wnt inhibitory factor-1 (WIF-1) 65, 
Fibulin-2 (FBLN2) 66, cadherin 4 (CDH4) 67, Tissue factor pathway inhibitor 2 (TFPI-2) 
68, Zinc finger protein 382 (ZNF382) 69 were epigenetically silenced by promoter 
hypermethylation in NPC. Moreover, many TSGs have been discovered in NPC, 
including Coiled-coil domain containing 19 (CCDC19) 70, Thy-1 cell surface antigen 
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(THY1) 71, Ubiquitin carboxyl-terminal esterase L1 (UCHL1) 72 and stratifin (SFN or 
14-3-3sigma) 73.  
 
 
Figure 2 Tumor suppressor genes inhibit cell growth.  
 
1.2.3 Resisting cell death 
Programmed cell death by apoptosis serves as a natural barrier to cancer development 
and cancer cells evolved a number of strategies to limit or circumvent apoptosis. EBV 
infection has been shown to provide anti-apoptotic functions in NPC. Firstly EBV 
encoded LMP1 74-76 and Epstein-Barr nuclear antigen 1 (EBNA1) 77 were reported to 
inhibit apoptosis and contribute to the survival of NPC. Furthermore, EBV encoded 
miR-BART5 could target PUMA to promote host cell survival 78. More and more 
anti-apoptotic and pro-apoptotic factors have been identified in NPC. Bax inhibitor-1 
(Bi-1) 79, Hepatocyte growth factor (HGF) 80, B-cell CLL/lymphoma 2 (BCL2) 80, 
Survivin76, Claudin-1 (CLDN7) 81, CASP8 and FADD-like apoptosis regulator 
(CFLAR or FLIP) 82 and Cellular inhibitor of apoptosis protein 2 (c-IAP2) 83 were 
overexpressed in NPC and mediated apoptosis-resistance in NPC. However many 
proapoptotic factors, such as Caspase-8 84 85, Zinc finger protein ZNF382 69, CKLF-like 
MARVEL transmembrane domain containing 3 (CMTM3) 86 and Prostate apoptosis 
response-4 (Par-4) 75, 87, were found to be downregulated in NPC. 
 
1.2.4 Inducing angiogenesis 
Like normal tissues, tumors require provision of nutrients and oxygen as well as an 
ability to evacuate metabolic wastes and carbon dioxide. Hence angiogenesis is very 
important during tumor development 88 (Figure 3). EBV has been verified to regulate 
angiogenesis in NPC 89. EBV encoded LMP1 enhanced angiogenesis in NPC by 
induction of interleukin-8 (IL-8) 90 and cyclooxygenase-2 (COX-2) 91. Furthermore, 
EBV-encoded EBNA1 could also promote angiogenesis in NPC 92. In addition, 
Vascular endothelial growth factor (VEGF) 93, Macrophage migration inhibitory factor 
(MMIF) 94, Hepatocyte growth factor (HGF) 95could induce angiogenesis in NPC. 
However matrix metalloproteinase-19 (MMP19) 96, Cysteine-rich intestinal protein 2 
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(CRIP2) 97 and Fibulin-2 (FBLN2) 66 had anti-angiogenic role and were downregulated 
in NPC.  
 
Figure 3 The angiogenic switch is necessary for tumor growth and metastasis. (Adapted from 
“Tribute to Judah Folkman, Father of Angiogenesis” from OncTalk. 
http://onctalk.com/2008/01/22/folkman-tribute/)  
 
1.2.5 Activating invasion and metastasis 
The multistep process of invasion and metastasis has been schematized as a sequence of 
discrete steps, often termed the invasion-metastasis cascade 98. This process includes 
several steps, beginning with local invasion, then intravasation by cancer cells into 
nearby blood and lymphatic vessels, transit of cancer cells through the lymphatic and 
hematogenous systems, followed by escape of cancer cells from the lumina of such 
vessels into the parenchyma of distant tissues (extravasation), the formation of small 
nodules of cancer cells (micrometastases), and finally the growth of micrometastatic 
lesions into macroscopic tumors, this last step being termed ‘‘colonization.’’ 53, 99 
(Figure 4). EBV encoded LMP1 could enhance NPC cell migration and invasion by 
induction of Snail 100, Decoy receptor 3 101, matrix metalloproteinase (MMP-1) 102 , 
matrix metalloproteinase 9 (MMP9) 27 and MicroRNA-10b103. EBV encoded LMP2A 
could induce an epithelial-mesenchymal transition in NPC and also contribute to 
invasion and metastasis of NPC 104. Several genes such as Fibroblast growth factor 8 
(FGF8b) 105, VEGF 106, Centromere protein F (CENP-F) 107, Transient receptor 
potential melastatin 7 (TRPM7) 108, Hepatocyte growth factor (HGF) 109, Bcl-2 and 
MMP2 110, Caveolin-1 and CD147 38, Cathepsin L 111, Chemokine (C-X-C motif) 
receptor 4 (CXCR4) 112 were found to be overexpressed in NPC and correlated with 
invasion and metastasis in NPC. On other hand, E-cadherin113, Non-metastatic cells 1, 
protein (NM23A) expressed in (NME1) 114, Toll-like receptor 3 (TLR3) 115, 
NPC-associated gene 6 (NGX6) 116, Fibulin-3 117, Phosphatidylethanolamine binding 
protein 1 (RKIP) 118, 14-3-3 sigma 119 were downregulated in NPC and had the ability 
to suppress cell migration and invasion in NPC cells.  
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Figure 4 The invasion-metastasis cascade. (Adapted from 99) 
 
1.2.6 Enabling replicative immortality 
Cancer cells require unlimited replicative potential in order to generate macroscopic 
tumors. Telomeres protecting the ends of chromosomes are centrally involved in the 
capability for unlimited proliferation120. Telomerase, the specialized DNA polymerase 
that adds telomere repeat segments to the ends of telomeric DNA, was usually 
expressed in many human cancer cells 121-123. Telomerase activity is frequently found in 
metaplastic and malignant human nasopharyngeal tissues124 and may be useful as a 
diagnostic marker in the detection of tumor cells in recurrent NPC, but not in primary 
NPC125. EBV encoded LMP1 could activate telomerase through c-myc 126 and led to 
immortalize primary cultures of nasopharyngeal epithelial cells 127. However LMP2A 
was shown to inhibit telomerase activity in epithelial cells128. Protein kinase C has been 
shown to be involved in the regulation of telomerase activity by direct or indirect 
phosphorylation of telomerase proteins in vivo in NPC 129 130. Furthermore, BMI1 
polycomb ring finger oncogene (Bmi-1) could immortalize primary human 
nasopharyngeal epithelial cells, and was a novel molecular marker of NPC progression 
131.  
 
1.2.7 Genome instability and mutation 
A large number of CGH (Comparative genomic hybridization )-based studies on NPC 
lead to the identification of consistent gain at chromosome 1q, 3q, 8q, 12 and loss at 3p, 
9p, 11q, 14q 132-133. Furthermore, using array based CGH, frequent amplifications were 
detected for several oncogene loci, including MYCL1 at 1p34.3 (66.7%), TERC at 
3q26.3 (46.7%), ESR at 6q25.1 (46.7%), and PIK3CA at 3q26.3 (40%)134. The most 
frequent LOHs (losses of heterozygosity) were observed at chromosome 3p, 9p, and 
14q in NPC, which is in agreement with the CGH based findings 135-138. PIK3CA gene 
amplification is frequent in NPC and occurs in the advanced stage 139. High frequency 
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somatic mutations in RASSF1A is seen 140. Moreover, mitochondrial DNA somatic 
mutations are frequent in NPC 141. 
 
1.2.8 Other hallmarks and characteristics 
The role of defective immunological monitoring of tumors seem to be validated by the 
striking increases of certain cancers in immunocompromised individuals 142.  EBV 
encoded EBERs induced the expression of insulin-like growth factor 1 (IGF-I) in NPC 
cells and modulated the innate immunity system143. Inhibition of NF-kB by EBV 
encoded EBNA1 is employed by viruses as an immune evasion strategy which is also 
closely linked to oncogenesis during persistent viral infection 144. The imbalances of 
T(reg) and effector T cell phenotypes and down-regulation of signal-transducing 
molecules in TILs, play important roles in suppression of immune response and 
immune evasion of NPC145. 
 
Tumor associated inflammatory response had an unanticipated effect of enhancing 
tumorigenesis and progress by supplying bioactive molecules to the tumor 
microenvironment. Tumor necrosis factor alpha (TNFα) is an inflammatory cytokine 
that is present in the microenvironment of many tumors and is known to promote tumor 
progression. Blood level of TNF-alpha in NPC was higher than that of healthy controls 
146. Furthermore, TNFα-inducible protein 2 (TNFAIP2), which was induced by TNFa, 
promoted migration in NPC and its expression predicted distant metastasis of NPC 
patients 147. Moreover, the increase of programmed death-1-expressing intratumoral 
CD8 T cells predicts a poor prognosis for NPC.148 
 
Moreover, cancer cells could reprogram their glucose metabolism and their energy 
production by glycolysis (Figure 5) 149. HIF1a had the capability to upregulate 
glycolysis in cancer cells 150. HIF1a was found to be overexpressed in NPC 151, which 
suggested that NPC cells also reprogrammed energy metabolism.  
 
 
Figure 5 Tumor cells mainly generate energy by glycolysis, while the oxidative 
phosphorylation is switched off (the Warburg effect).  
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1.3 BIOMARKERS FOR NPC 
 
1.3.1 EBV markers 
EBV has been verified to correlate with the etiology of NPC, and EBV-specific 
antibody-based assays such as serum titers of IgA antibodies to viral capsid antigen 
(VCA), early antigen (EA), nuclear antigen (EBNA) and DNase assay have been 
commonly used for at least twenty years as standard markers for screening and 
monitoring the disease152. Serological levels of VCA/IgA and EA/IgA were 
significantly associated with increased risks for NPC, and VCA/IgA had better 
predictive performance for NPC incidence than EA/IgA153. Some studies suggested that 
combination of EBV EA and EBNA recombinant antigens has high sensitivity and 
acceptable specificity and accuracy in early diagnosis and mass screening of NPC 
patients154-155. Antibodies targeting the BARF1 protein could be used as a new 
diagnostic tool to identify NPC patients33. Recently, one paper reported that 
pretreatment serologic antienzyme rate (AER) of EBV DNase-specific neutralizing 
antibody could serve as an independent prognostic marker complementing TNM stage 
in NPC 156. EBV viral load measurement in serum or plasma has been shown to be 
useful for diagnosis and monitoring in NPC patients. It can reflect tumor stage, is 
predictive for overall survival, correlated with the residual tumor load after treatment 
and accurately predict recurrence and prognosis 157-161. Hence cell-free EBV DNA 
could become one of the potential diagnostic and prognostic molecular markers for 
NPC.  
 
1.3.2 Epigenetic markers 
DNA methylation of TSGs is widely known to be an early event in carcinogenesis and 
methylation analysis in the promoter of TSGs may serve as a complementary marker 
for identifying early cases. Epigenetic changes are frequently found in NPC and the 
high detection rate in body fluids suggests its potential application in non-invasive 
screening of NPC or detection of residual carcinoma after treatment 162. Hutajulu et al 
163 found that combined analysis of five methylation markers (RASSF1A, p16, WIF1, 
CHFR and RIZ1) in brushings shows good discrimination between NPC and non-NPC 
with a detection rate of 98% in a high risk population. Moreover, hypermethylated 
promoter DNA of at least one of the three genes (CDH1, DAPK1, and p16) was 
detectable in post-treatment plasma of 5 of 13 (38%) recurrent NPC patients and none 
of the patients in remission, which suggested that cell-free circulating methylated gene 
promoter DNA is a potential useful serological marker in assisting in screening of 
potentially local or regional recurrent NPC 164.   
 
1.3.3 Genomic markers  
Several genomic markers in NPC have been identified as possible candidates for risk 
prediction. Familial NPC has been linked to genetic predispositions such as leukocyte 
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antigen (HLA) genotypes 165-166 and susceptibility loci on chromosome 3p 219, 
4p15.1-q12 10and 5p 1311. Recently, a genome-wide association study was performed 
using 464,328 autosomal single-nucleotide polymorphisms (SNPs) in 1,583 NPCs and 
1,894 controls, and three new susceptibility loci, including TNFRSF19 on 13q12, 
MDS1-EVI1 on 3q26 and the CDKN2A-CDKN2B gene cluster on 9p21 were 
identified166. Moreover, the allele of Cav-1 T29107A was found to be protective against 
the development of NPC and may be a novel useful genomic marker for early screening 
and prediction of NPC 167. The endothelin A receptor (EDNRA) / H323H 
polymorphism was a novel and independent prognostic marker for patients with 
locoregionally advanced NPC 168. MDM2 SNP309 T/G polymorphism 169 and Tumor 
necrosis factor alpha 308G/A polymorphism 170 could be considered a risk marker for 
the development of NPC. Moreover, the FAS-670 G allele 171 and MCP-1 SNP-2518 172 
have been suggested as a genetic marker for risk of distant metastasis of NPC patients.   
 
1.3.4 Protein and microRNA markers 
Many aberrantly expressed cellular genes have been found in NPC cancer cells and 
patients’ serum, and many studies indicated that the expression pattern of some 
particular genes could be the biomarkers for NPC diagnosis and prognosis prediction. 
Wang et al 173 developed a new NPC-SVM classifier, which integrated patient sex and 
the protein expression level of seven genes, including EBV encoded LMP1, CD147, 
caveolin-1, phospho-P70S6 kinase, matrix metalloproteinase 11 (MMP11), survivin, 
and secreted protein acidic and rich in cysteine (SPARC). The NPC-SVM classifier 
distinguished patients with NPC into low- and high-risk groups with significant 
differences in 5-year DSS in the evaluated patients (87% v 37.7%; P < .001) in the 
validation cohort. Moreover, the patients with NPC with higher levels of interleukin-8 
(IL-8), vascular endothelial growth factor (VEGF), macrophage inflammatory protein 
(MIP)-3α, and EBV DNA in plasma had worse prognosis for overall survival 174. Until 
now, useful miRNA markers have not yet been identified in either NPC tumor tissue or 
the NPC patient serum.  
 
1.3.5 Other biomarkers 
Metabolic profiling revealed that kynurenine, N-acetylglucosaminylamine, 
N-acetylglucosamine and hydroxyphenylpyruvate are increased in NPC patient sera.  
After radiotherapy, these four metabolites decreased gradually, tended to normalize, 
and were associated with rate of tumor reduction. The results revealed that kynurenine, 
N-acetylglucosaminylamine, N-acetylglucosamine and hydroxyphenylpyruvate are 
potential markers for NPC diagnosis 175. 
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2 AIMS OF THE STUDY 
 
Currently, NPC prognosis evaluation and the choice of treatment are mainly based on 
the tumor-node-metastasis (TNM) staging system. However, NPC patients with the 
same clinical stage often present with different clinical courses, suggesting that the 
TNM stage is insufficient to provide satisfactory prediction of prognosis. Therefore, it 
is important to find molecular biomarkers, which can help clinicians to identify high 
risk NPC patient, thus improving prognosis prediction, and therapeutic interventions in 
NPC patients. 
 
To identify novel prognostic markers for NPC, we have studied the following aspects: 
 
1. Investigating the expression pattern and clinical significance of Caveolin-1 and 
CD147 in NPC, and their possible functional mechanism.  
 
2 Exploring the expression pattern of miR-155 and its possible mechanism of action in 
NPC, identifying targets and evaluating prognostic value in NPC  
 
3 Investigating the expression of Syk and evaluating its prognostic value in NPC 
 
4 Identifying putative TSGs in Chr.3 in NPC, and their possible regulatory mechanism 
in NPC 
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3 MATERIALS AND METHODS 
 
3.1 METHODS FOR BIOMARKER EVALUATION 
To evaluate the clinical value of certain biomarkers, immunohistochemistry was 
performed in NPC clinical samples, and then the prognostic value was analyzed by 
Kaplan-Meier analysis and log-rank tests. The detailed information and protocol of 
these methods are described in Paper I, II and III.  
 
Clinical Samples 
For this retrospective study, archival formalin-fixed, paraffin-embedded (FFPE) tissue 
specimens from primary NPC patients with clinical information were obtained from 
Sun Yat-Sen University Cancer Center (Guangzhou, China). All NPC samples in our 
study were obtained before treatment with standard curative radiotherapy, with or 
without chemotherapy. The study was approved by the Research Ethics Committee of 
Sun Yat-Sen University Cancer Center, Guangzhou, China (Reference number: 
YP-2009175) and Karolinska Institutet, Stockholm, Sweden (Reference number: 
00-302).  
 
Immunohistochemistry 
Immunohistochemistry is applicable for the detection of protein expression in tissue 
sections with specific antibodies, which can provide both location and intensity of 
positive signal. The immunohistochemistry results were evaluated and scored by senior 
pathologists without knowledge of the clinicopathological outcomes of the patients. 
Then the NPC patients were divided into high expression group and low expression 
group according to the composite pathology score which each patient was given.  
 
Statistical analysis 
SPSS12.0 software was used to statistically evaluate the clinical biomarker data. The 
association between biomarker expression and clinicopathological parameters were 
assessed using a Chi-Square test. Kaplan-Meier analysis and log-rank tests were used to 
assess the survival rate and to compare the difference in survival curves. Differences 
were considered significant when p < 0.05. 
 
3.2 METHODS FOR FUNCTIONAL STUDIES OF BIOMARKERS 
To study the function of the certain biomarkers, gene transfection technology was used 
in NPC cell lines to knockdown or overexpress protein. Transwell migration assay was 
performed to evaluate the migration ability of the cells. All the detailed methods used 
can be found in section “Materials and methods” of Paper I.  
 
Cell lines 
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Human NPC cell lines CNE1 and CNE2 (EBV negative, from Cancer Center, Sun 
Yat-sen University, China) were used for gene transfection. 
 
Transfection 
Transfection is the process of delivery of genetic material (DNA or RNA) into cells, 
such as human cancer cells. In the present study, Lipofectamine 2000 (Invitrogen, USA) 
was used to transfer specific small interference RNA (siRNA) or vectors for 
overexpression of proteins to NPC cell lines transiently. Since the genetic material 
(DNA or RNA) introduced in the transfection process is usually not inserted into the 
genome of host cells, the introduced DNA is lost after one or few rounds of mitosis. 
Hence different time points after transfection have been checked and the most efficient 
time point was chosen.  
 
Transwell migration assay 
Transwell migration assay is employed to evaluate the migration ability of cells in vitro 
using 24-well transwell units (Corning, USA) with a 8 μm pore size polycarbonate filter. 
Cell suspensions without FCS were placed in the upper chamber, and medium with 
10% FCS was added to the bottom chamber. After overnight incubation, the top cells in 
the upper chamber were removed while the cells in the lower were fixed and stained 
with 4,6-diamidino-2-phenylindole (DAPI; 5 μg/ml) to visualize nuclei. The number of 
migrating cells was counted under a fluorescence microscope  
 
3.3 METHODS FOR STUDIES OF REGULATION BY MIRNAS 
To identify a direct target of a certain miRNA, software prediction was used and then 
luciferase reporter assay was performed for further validation. All the detailed methods 
used can be found in section “Materials and methods” of Paper II.  
 
Prediction miRNAs target analysis 
Since miRNAs bind to the 3’ UTR of their target mRNAs with imperfect base pairing, 
leading to mRNA degradation or translational inhibition (Figure 6), many algorithms 
have been developed to predict the putative targets of miRNAs. In the present study, 
the putative targets of a certain miRNA were analyzed as follows176: Firstly, the 
analysis was done by using four algorithms, miRanda 177, TargetScan 178, PicTar 179 and 
miRBase 180 respectively. Since any of the four approaches generates an unpredictable 
number of false positives, the putative targets, commonly predicted by at least three of 
the algorithms, were chosen.  
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Figure 6 miRNA binds to the 3’UTR of its target mRNA with imperfect base pairing, 
leading to mRNA degradation or translational inhibition. RISC, RNA-Induced Silencing 
Complex; 3’UTR, 3’un-translated regions. 
 
Luciferase reporter assay  
To validate the direct target of a certain miRNA, luciferase reporter assay was 
performed. Firstly, the 3’ UTR sequences containing the putative miRNA target sites 
were inserted by cloning downstream from the luciferase reading frame in the plasmid 
pMIR-report-Vector (Figure 7A). Luciferase reporter assays were performed by 
transiently transfecting HEK 293T cells with pMIR-reporter-vector containing the 
3’UTR of the putative targets, together with miRNA mimic and pCMV-Renilla 
(internal control). Firefly and Renilla luciferase activities were measured consecutively 
by using Dual Luciferase Assay (Figure 7B).  
 
Figure 7 Luciferase reporter assay. (A) The 3’ UTR sequences containing the putative miRNA 
target sites were cloned into the downstream from the luciferase reading frame in the plasmid. (B) 
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A result was positive when the miRNA could repress the luciferase activity in the wild type 
3’UTR construct, but could not in the site-specific mutagenesis construct. 
 
3.4 METHODS FOR STUDIES OF EPIGENETIC REGULATION 
To investigate whether epigenetic modification might be involved in regulation of 
putative biomarkers, i.e. to identify epigenetically silenced biomarkers (tumor 
suppressor genes), Not I microarrays were performed to screen methylated or deleted 
genes in chromosome 3 in NPC and then Bisulfite sequencing and methylation specific 
PCR (MSP) were performed for further validation. All the detailed methods used can be 
found in section “Materials and methods” of Paper IV.  
Chr. 3 specific NotI microarrays 
Loss of heterozygosity (LOH) and cytogenetic studies have shown that frequent 
changes in Chromosome 3 (Chr. 3) is common in many tumors including NPC, 
harboring many TSGs 137-138, 181. Only a small fraction (0.1-0.05%) of the human 
genome containing NotI digested fragments and NotI sites are almost exclusively 
located in CpG islands and are closely associated with functional genes. Hence Chr. 3 
specific NotI microarray, covering 188 genes/ putative TSGs, was developed in Eugene 
Zabarovskys group to search methylated or deleted genes in Chr. 3182. The main 
objective is to prepare and to use Not I microarrays (NMA, i.e. glass microarrays with 
attached NotI DNA fragments) for comparison of normal and tumor cells at genomic 
level. The main idea of the approach is that NotI enzyme cuts only unmethylated CpG 
pairs inside the recognition site of the enzyme (5’-GCGGCCGC-3’) (Figure 8). This 
new type of microarrays opens new possibilities for large scale study of 
methylation/deletion patterns in normal and pathological cells 
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Figure 8 Schematic representation how NotI microarrays are employed to identify methylated 
or deleted sequences (The main idea of using NR for NotI microaarays). N and B represent Not I 
and BamH I / Bgl II sites, respectively. Methylated NotI sites are indicated by an asterisk. NR: NotI- 
representation. (Adapted from182) 
Bisulfite sequencing 
Bisulfite sequencing is the golden standard to detect methylation status of CpGs in a 
site-specific manner. Bisulfite treatment of DNA template converts cytosine residues to 
uracil, but has no effect on 5-methylcytosine residual (Figure 9). Hence bisulfite 
treatment could incorporate specific changes in the DNA sequence and this provides 
information at the single nucleotide level regarding the DNA methylation state. 
However the major challenge for bislphite sequencing technique is incomplete 
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conversion. If the conversion is incomplete, it will increase the possibilities of false 
positive result.   
 
 
Figure 9 Bisulfite-mediated conversion of cytosine to uracil.  
 
Methylation specific PCR (MSP) 
Methylation specific PCR (MSP) is the most widely and conveniently used technique 
for studying the methylation status of CpG islands. Cytosines in CpG islands in 
promoter region of many tumor suppressor genes are usually methylated in human 
cancers, while they are usually unmethylated in normal tissues. The differences 
between methylated and unmethylated alleles that arise from sodium bisulfite treatment 
are the basis of MSP, and the primers for MSP are designed according to these 
differences to distinguish the different methylation status. MSP is the simplest 
technique with relatively low cost to investigate methylation status of CpG islands. 
Because the DNA template is conversed and partially degraded after bisulfite treatment, 
optimizing the MSP reaction condition is critical to get the positive result.   
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4 RESULTS AND DISCUSSION 
 
4.1 UPREGULATION OF CAVEOLIN-1 AND CD147 EXPRESSION IN NPC 
ENHANCED TUMOR CELL MIGRATION AND CORRELATED WITH 
POOR PROGNOSIS OF THE PATIENTS (PAPER I) 
 
Expression of Cav-1 and CD147 and their associations with clinico- pathological 
parameters in NPC 
Cav-1 is a major structural component of caveolae, which are involved in several 
cellular functions, including vesicle trafficking, cholesterol homeostasis and signal 
transduction 183-184. Reduced Cav-1 expression has been reported in ovarian cancer185, 
breast cancer186 and lung cancer187. On the other hand, Cav-1 overexpression has been 
observed in bladder cancer188, prostate cancer189 and esophageal squamous cell 
carcinoma (ESCC) 190. Extracellular matrix metalloproteinase inducer (EMMPRIN), 
also named CD147, is a glycoprotein that belongs to the immunoglobulin superfamily 
191. Due to serendipitous observation, we thought the expression patterns of Cav-1 and 
CD147 in NPC was of interest. In the present study, Cav-1 and CD147 were found to 
be upregulated in NPC cell lines as well as in NPC clinical samples.  
 
We found that Cav-1 was expressed at a high level in 96 cases (49.5%) of NPC, which 
associated significantly with local recurrence (p = 0.038) and metastasis (p = 0.025) of 
NPC. No significant association between Cav-1 expression and age, gender and TNM 
stage of the patients was observed in this study. Overexpression of CD147 was 
observed in 117 cases (59.4%) of NPC, which was associated significantly with 
metastasis of the disease (p = 0.017). No significant association between CD147 
expression and age, gender, clinical staging and recurrence of the disease was observed 
in this study.  
 
Cav-1 overexpression was reported previously to be correlated with the metastasis of 
several malignancies, including prostate cancer 189, ESCC 190, breast cancer 192 and lung 
cancer 193. In the present study, we revealed that Cav-1 overexpression in NPC tumor 
cells was significantly correlated with recurrence (p = 0.038) and metastasis (p = 0.025) 
of the disease. Overexpression of CD147 in the tumor cells has been reported to be 
correlated with metastasis of breast cancer 194, and oral squamous cell carcinoma 195; 
and with poor prognosis of patients with ESCC 196, breast cancer 194, serous ovarian 
cancer 197 and gastric cancer 198. We found that CD147 overexpression in NPC tumor 
cells was significantly correlated with metastasis (p = 0.017) of the disease.  
 
Combined Cav-1 and CD147 overexpression predicts poor survival of the NPC 
patients 
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Cav-1 overexpression in tumor cells also has been reported to be correlated with poor 
prognosis in patients with ESCC 190, renal clear cell carcinoma 199, prostate cancer 200, 
lung cancer 201, and pancreatic ductal adenocarcinoma 202. In the present study, we 
revealed that Cav-1 overexpression in NPC tumor cells was significantly correlated 
with poor prognosis in NPC patients. Several recent studies have demonstrated that 
overexpression of CD147 is correlated with poor prognosis in human cancers, including 
ESCC 196, breast carcinoma 194, serous ovarian carcinoma 197 and gastric carcinoma 198. 
We found that CD147 overexpression in NPC tumor cells was significantly correlated 
with poor prognosis in NPC patients. In addition, we found that NPC patients with 
overexpression of both Cav-1 and CD147 in tumor cells had a significantly worse 
prognosis and a significantly lower five-year overall survival rate relative to NPC 
patients with low expression of Cav-1 and / or CD147 (p = 0.001).  
 
Cav-1 and CD147 increase the migration ability of CNE1 and CNE2 cells through 
increasing the secretion of MMP-3 and MMP-11 (active) 
Recent evidence suggests a central role for Cav-1 in the regulation of cellular invasion 
and metastasis 203-204. CD147 is enriched on the plasma membrane of tumor cells and 
triggers the production or release of MMPs in surrounding mesenchymal cells and 
tumor cells 205-206.  In this study, Cav-1 and CD147 overexpression were found to be 
associated with metastasis in NPC patients. Transwell migration assays further revealed 
that loss of Cav-1 and CD147 expression inhibited CNE1 and CNE2 cell migration 
ability, whereas Cav-1 and CD147 overexpression promoted cell migration ability. 
Taken together, our results are consistent with previous studies of Cav-1 and CD147 
expression in other malignancies, and indicate that these two genes may play a key role 
in the invasion and metastasis of NPC.  
 
How do Cav-1 and CD147 regulate the invasion and metastasis of NPC? Growing 
evidence suggests a close association between Cav-1, CD147 and the expression or 
secretion of MMPs. Overexpression of Cav-1 in HEK293 cells decreased MMP-1 
secretion in a co-culture assay with primary human fibroblasts 207, and overexpression 
of Cav-1 in metastatic mammary tumor cells could inhibit MMP-2 and MMP-9 
secretion, although the expression of MMP-2 and MMP-9 in whole cell lysates was not 
altered 186. In contrast, Cav-1 can induce MMP-11 secretion and the invasive potential 
of a murine hepatocarcinoma cell line 208. CD147 is a tumor cell-derived MMP inducer 
that is expressed on the tumor cell surface and triggers the production or release of 
MMP-1, MMP-2, MMP-3, MMP-9, MT1-MMP and MT2-MMP in the surrounding 
mesenchymal cells and tumor cells 205-206, 209-211. In the present study, we found that the 
suppression of Cav-1 and CD147 expression led to decrease MMP-3 and MMP-11 
(active) secretion in CNE1 and CNE2 cells, whereas overexpression of Cav-1 in CNE1 
and CNE2 cells promoted MMP-3 and MMP-11 (active) secretion. Furthermore, 
suppression of CD147 expression in Cav-1 overexpressing CNE1 cells could also lead 
to decrease of MMP-3 and MMP-11 (active) secretion. Taken together, these results 
indicate that Cav-1 and CD147 overexpression in NPC tumors can promote tumor cell 
migration by stimulating MMP-3 and MMP-11 (active) secretion in NPC tumor cells, 
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and Cav-1 regulates MMP-3 and MMP-11 (active) secretion partially, maybe directly, 
through CD147 in NPC tumor cells.  
 
4.2 UPREGULATION OF MIR-155 IN NPC IS PARTLY DRIVEN BY LMP1 
AND LMP2A AND DOWNREGULATES A NEGATIVE PROGNOSTIC 
MARKER JMJD1A (PAPER II) 
 
EBV LMP1 and LMP2A further enhance miR-155 expression in NPC 
MiR-155 was upregulated in several human tumors, such as lymphoma 212-213, thyroid 
carcinoma214 , breast cancer215-216, colon cancer215, cervical cancer217, pancreatic 
cancer218, and lung cancer219. Furthermore, elevated expression of miR-155 was 
associated with poor prognosis of pancreatic cancer218 and lung cancer 219. Recently, 
Chen et al used a stem-loop real-time-PCR method to quantify the expression levels of 
270 human miRNAs in 13 NPC samples and 9 adjacent normal tissues. They identified 
35 miRNAs whose expression levels were significantly altered in NPC samples, 
including upregulation of miR-155 220. In the present study, we reported that miR-155 
expression was enhanced in NPC. 
 
Several studies have demonstrated that EBV could induce miR-155 expression in B 
cells and cell lines which in turn modulates EBV-regulated pathways 221-223. 
LMP1222-225 and EBNA2222 were responsible for the upregulation of miR-155 after 
EBV infection of B-lymphocytes, while LMP2A did not influence miR-155 
expression223, 225. Furthermore LMP1 was demonstrated to trans-activate miR-155 
transcription through the NF-kappaB and AP1 pathways 223, 225. In contrast, EBV did 
not induce the expression of miR155 in HEK 293 and Hela cells222. We found that both 
LMP1 and LMP2A could induce the miR-155 expression in NPC CNE1 and TW03 
cells. To our knowledge, this is the first report that LMP2A could induce miR-155 
expression in NPC. Guasparri et al reported that EBV LMP2A protein could affect 
LMP1-mediated NF-κB signaling and survival of lymphoma cells, hence LMP2A 
might increase miR-155 expression through NF- kappaB pathway 30.  
 
In addition, LMP1 was reported to induce the expression of miR-146a in 
B-lymphocytes 224. However, in our study, we found that neither LMP1 nor LMP2A 
could induce the miR-146a expression in NPC cells. These differences might be due to 
different tumor cell type backgrounds.  
 
LMP1 and LMP2A were expressed in approximately 65% and 45% NPC patients, 
repectively 25, 28, and miR-155 was also found to be upregulated in many human tumors, 
which were not related to EBV 214-219. Furthermore, in our study, both CNE1 and TW03 
were EBV negative NPC derived cell lines, the expression of miR-155 in these two cell 
lines was higher than that in the immortalized nasopharyngeal epithelial cell line NP69. 
Hence there are also other factors than EBV genes which might upregulate miR-155 
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expression in NPC. TGF-beta (Transforming Growth Factor – beta) was verified to 
induce miR-155 expression by increased promoter activity due to SMAD4 (SMAD 
family member 5)226. Elevated serum levels of TGF-beta1 was also found in NPC 
patients227. Hence TGF-beta and SMAD4 pathways might also contributed to miR-155 
overexpression in NPC. 
 
Identification of JMJD1A as a direct target of miR-155 in NPC 
At present, many direct targets of miR-155 have been identified and show oncogenic 
features of miR-155. MiR-155 promoted the proliferation of breast cancer cells through 
down-regulation of SOCS1 (Suppressor of cytokine signaling 1) 228 and FOXO3a 
(forkhead box O3) 229. MiR-155 has also been reported to be involved in the 
development of lymphoma by targeting SMAD5 (SMAD family member 5) 230 and 
SHIP1 (inositol polyphosphate-5-phosphatase) 231. MiR-155 could promote pancreatic 
tumor development through downregulation of TP53INP1 (Tumor protein p53 induced 
nuclear protein 1) 232. Moreover, some other genes implicated in differentiation, 
inflammation and transcriptional regulation, were direct targets of miR-155, including 
HIF-1 (Hypoxia-inducible factor 1)233-234, BACH1 (BTB and CNC homology 1, basic 
leucine zipper transcription factor1)223, 233, HIVEP2 (Human immunodeficiency virus 
type I enhancer binding protein 2)223, IKKɛ (Inhibitor of kappa light polypeptide gene 
enhancer in B cells, kinase ɛ)235, and so on. In our study, we found that miR-155 could 
repress endogenous JMJD1A and BACH1 protein expression in NP69 cells. Luciferase 
reporter assay was performed to identify both JMJD1A and BACH1 as direct targets of 
miR-155 in NPC cells. This is the first report that JMJD1A is a direct target of miR-155. 
Furthermore, JMJD1A and BACH1 are downregulated in NPC cell lines and NPC 
tumor tissues.  
 
Downregulation of JMJD1A predicts poor survival in NPC 
The expression of JMJD1A and BACH1 was detected by immunostaining in 185 NPC 
cases. Low expression of JMJD1A was observed in 113 (61%), and was associated 
significantly with N-stage (p = 0.023). No significant association was seen between 
JMJD1A expression and age, gender, T stage, TNM stage, recurrence or metastasis. In 
addition, no significant association was seen between BACH1 expression and age, 
gender, T stage, N stage, TNM stage, recurrence or metastasis. 
 
The five-year overall survival rate was 61.3% for patients with low JMJD1A expression 
(n = 113), and 77.2% for patients with high JMJD1A expression (n = 72), which was a 
significant difference (p = 0.021). The five-year overall survival rate was 66.8% for 
patients with low BACH1 expression (n = 94), and 68.2% for patients with high 
BACH1 expression (n = 91), which was not significant (p = 0.759). Furthermore, the 
five-year disease-free survival rate was 57.0% for NPC patients with low levels of 
JMJD1A expression (n = 113), and 68.7% for those with high levels of JMJD1A 
expression (n = 72), and this difference in the disease-free survival rate was significant 
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(p = 0.049). No significant difference was seen in the disease-free survival rate of NPC 
patients, with or without BACH1 overexpression (p = 0.895). 
 
Adam et al. 236 demonstrated that loss of JMJD1A is sufficient to reduce tumor growth 
of renal cell carcinoma and colon carcinoma in vivo, suggesting that function of 
JMJD1A in different cells and tissues depend on cell microenvironment. Hence, the 
function of JMJD1A and BACH1 in NPC deserve for further attention.  
 
 
4.3 ELEVATED SYK EXPRESSION CORRELATES WITH LMP2A 
EXPRESSION IN NPC AND PREDICTS POOR PROGNOSIS (PAPER 
III) 
 
High expression of Syk correlates with clinicopathological parameters and predicts 
poor survival in NPC 
Spleen tyrosine kinase (Syk) is a nonreceptor tyrosine kinase that contains tandem NH2 
terminal Src homology 2 domains, multiple tyrosine phosphorylation sites, and a 
COOH-terminal tyrosine kinase domain237. Moreover, Syk promoter hypermethylation 
leads to gene silencing and reduced Syk expression correlates with tumor metastasis 
and poor prognosis in breast cancer238, pancreatic adenocarcinoma239, hepatocellular 
carcinoma240, bladder carcinoma241, and gastric carcinoma242. In contrast, 
overexpression of Syk is associated with recurrence and poor prognosis of squamous 
cell carcinomas of the head and neck (SCCHN) patients 243. In addition, overexpression 
of Syk has also been observed in peripheral T-cell lymphomas 244-245, chronic 
lymphocytic leukemia246, and B-lineage acute lymphoblastic leukemia247.  
 
In this study, we showed that high expression of Syk was significantly associated with 
T-stage and local recurrence of NPC. Our data also indicated that NPC patients with 
high expression levels of Syk had shorter survival time, shorter disease free time, and 
that Syk was an independent prognosis factor in NPC. These results are consistent with 
the study of another head and neck cancer, SCCHN, in which, Sutima et al. 243 reported 
that overexpression of Syk was associated with recurrence and poor prognosis of the 
patients.  
 
Syk has been reported to be involved in tumor metastasis in many human cancers, 
either suppressing or enhancing metastasis. Reduced expression of Syk could promote 
cell migration in breast cancer 238, while overexpression of Syk could enhance cell 
migration in SCCHN cells 243 . However, in our study, no significant correlation was 
found between Syk expression and tumor metastasis.It would have been highly 
interesting to compare Syk expression in paired samples of primary tumors and 
metastasis, but such clinical material with sufficient number of samples has not been 
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made available as yet (biopsies are rarely removed by surgery). Taken together, our 
results indicate that Syk may play a role in local NPC recurrence, and correlates with 
poor prognosis of NPC patients, suggesting that Syk could be used clinically as one of 
several biomarkers for NPC prognosis.  
 
LMP2A induces Syk expression in NPC 
It has been demonstrated that Syk could bind to the ITAM motif in EBV encoded 
LMP2A in B cells and epithelial cells 248-249. Moreover, Syk interacts selectively in 
immune cells with proteins containing a phosphorylated immunoreceptor 
tyrosine-based activation motif (ITAM) through its distinct tandem Src homology 2 
domain 250. LMP2A, which is detected in the majority of NPC, contains an ITAM 251. In 
our study, we could confirm the interaction and co-localization of LMP2A with Syk as 
demonstrated by co-IP and IF in NPC cell lines. Interestingly, our results of ISH and IF 
indicated that LMP2A could enhance Syk expression in two NPC-cell lines SUNE1 and 
CNE2 cells, and LMP2A high expression positively correlated with Syk high 
expression in NPC clinical samples. However, LMP2A has been reported to promote 
the degradation of Syk in B cells by ubiquitination 252-253. The increased expression of 
Syk in LMP2A positive NPC might be a compensation for a shorter half life of Syk 
when LMP2A binds and affects Syk degradation. LMP2A was reported to induce cell 
migration and invasion in epithelial cells. 29. Lu et al 249 further demonstrated that 
endogenous Syk was activated in epithelial cells in the presence of LMP2A, and that 
Syk was required for LMP2A-triggered cell migration in epithelial cells. Taken together, 
these data suggested that LMP2A expression partly contributes to Syk high expression 
in NPC, and that Syk and LMP2A may have co-operative roles in NPC development. 
The precise relationship between Syk and LMP2A and the mechanism by which 
LMP2A induces Syk in NPC deserve further experimental studies.  
 
4.4 WNT7A AND ITGA9 WERE HYPERMETHYLATED AND 
DOWNREGULATED IN NPC (PAPER IV) 
 
Screening for potentially methylated genes in NPC using NotI micrarrays
Loss of heterozygosity (LOH) and cytogenetic studies have shown that frequent 
changes in Chromosome 3 (Chr. 3) is common in many tumors including NPC, 
harboring many TSGs 181. To screen the potentially methylated or deleted genes in chr. 
3 in NPC, Not I micorarrays were performed on genomic DNA from three NPC 
biopsies (T9, T10 and T18), two normal nasopharyngeal epithelia tissues (N1 and N2), 
three NPC cell lines (CNE1, TW03 and C666-1) and one normal nasopharyngeal 
epithelium derived cell line NP69. Ten genes (WNT7a, FGD5, ITGA9, RBSP3, 
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ALDH1L1, NUDT16P, ZIC4, EPHB3, BCL6 and FGF12) were identified as showing 
reduced signal suggesting methylation or deletion. These genes were selected for 
further validation by MSP and Q-PCR. Among these, we selected two interesting 
genes WNT7a and ITGA9, for further study. 
 
WNT7a and ITGA9 were hypermethylated in NPC 
The methylation status of the CpG rich region in the WNT7a gene promoter was 
investigated by bisulfite sequencing in four NPC biopsies (T1, T2, T5 and T6) and 
one normal nasopharyngeal epithelia biopsy (N10). Twenty-three CpG sites were 
included in this region. The WNT7a promoter was partially methylated in the four 
NPC samples, whereas there was almost no of methylation in the control sample. 
Similarly, methylation status of CpG island in ITGA9 gene intron 1 region was 
investigated in the same samples. Fourteen CpG sites were included in this region. 
The CpG island in ITGA9 gene intron 1 region was partially methylated in four NPC 
samples, whereas it was totally free of methylation in the normal sample.  
To investigate whether 5-aza-CdR could restore WNT7a and ITGA9 expression, NPC 
CNE1 and TW03 cell lines were treated with 10 μM of the demethylating agent 
5-aza-2′-deoxycytidine (5-aza-CdR) for 96 h. QPCR was performed to detect WNT7a 
and ITGA9 expression in 5-aza-CdR treated and untreated NPC cell lines. Both 
WNT7a and ITGA9 expression were found to be restored after 5-aza-CdR treatment. 
 
Downregulation of WNT7a and ITGA9 were found in NPC 
QPCR was performed to detect WNT7a and ITGA9 expression in the three clinical 
NPC samples (T2, T3 and T4) as well as in four normal epithelial tissues (N2, N4, N5 
and N7). The average expression levels of WNT7a and ITGA9 in NPC tumors (9.4±
7.7 fold; 4.0±2.6 fold) were downregulated, compared with the expression in normal 
epithelial tissues (28.9±18.9 fold; 19.9±10.2 fold). Moreover, immunostaining was 
performed to evaluate the expression of WNT7a and ITGA9 in three cases of NPC 
tumor cells and adjacent normal nasopharyngeal epithelium. Strong expression of 
WNT7a and ITGA9 were observed in the membrane and cytoplasm of normal 
adjacent nasopharyngeal epithelium cells, while weak expression of WNT7a and 
ITGA9 were observed in NPC tumor cells.  
In Non-Small Cell Lung Cancer (NSCLC) cells, the re-expression of WNT-7a and 
signaling through Fzd-9 are associated with increased differentiation and thus 
represent a tumor suppressor pathway 254. It has been demonstrated that WNT7a is a 
positive regulator of E-cadherin expression in lung cancer cells  and E-cadherin is 
also downregulated in NPC . Pharmacologic reversal of WNT7a losses could be 
achieved with the use of inhibitors of GSK3β, HDACs, or in some cases only with 
combined treatment . 
255
256
255
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ITGA9 is abundantly expressed in lung cancers in general and small cell lung cancers 
(SCLC) in particular. Its aberrant upregulation in the SCLC samples, both cell lines and 
primary tumors has been suggested to play a role in metastasis and in the progression 
to more malignant phenotypes 257. This is in contrast to the downregulation of ITGA9 
in NPC and in human papilloma virus associated head and neck squamous cell 
carcinoma 258. 
In conclusion, we found that WNT7a and ITGA9 are methylated and downregulated in 
Chinese NPC patients. As both proteins execute significant functions related to the 
tumor cell biology, in depth functional studies has to be pursed to understand the 
functional role of WNT7a and ITGA9 downregulation in the development of NPC. 
With such studies these two genes might be useful for improved diagnosis and 
treatment in the future.  
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5 CONCLUDING REMARKS 
 
Nowadays, several biomarkers in serum, saliva and tissue have been identified for NPC 
screening, early diagnosis and prognosis prediction. Using serological biomarkers is a 
common and convenient way to screen and monitor NPC, such as EBV-specific 
antibodies in serum for early diagnosis and mass screening of NPC patients154-155, and 
EBV viral load in serum for diagnosis and monitoring recurrence in NPC patients 157-161 
and Cell-free circulating methylated gene promoter DNA in assisting in screening of 
potentially local or regional recurrent NPC 164. Using epigenetic biomarkers in saliva 
and body fluids is a non-invasive way to screen and detect residual carcinoma after 
treatment of NPC 162. Genomic biomarkers could be used for screening the high risk 
population through NPC specific susceptibility loci9-11. Protein biomarkers in tissues 
could be used for diagnosis and prognosis prediction of NPC 173.  
 
In this study, we have tried to identify the new protein biomarkers and epigenetic 
biomarkers for NPC early diagnosis and prognosis prediction. Several approaches to 
identify biomarkers of significant clinical and functional interest have been explored. 
We have investigated some genes with considerable impact in other tumors (Paper I 
and III), genes regulated by miRNAs (Paper II) and epigenetically deregulated genes 
(Paper IV). In paper I, II and III, four protein biomarkers have been identified for 
prognosis prediction of NPC, and a larger scale of NPC samples are needed for further 
validation. In paper IV, two putative epigenetic biomarkers have been found, and 
further study is needed to evaluate their potentials for early diagnosis of NPC using 
either saliva or blood.  
 
These are my main conclusions from the work: 
 
1. Cav-1 and CD147 overexpression predict poor NPC prognosis and enhanced tumor 
cell migration, which is associated with MMP-3 and MMP-11 (active) secretion. 
2. Upregulation of miR-155 in NPC is partly drived by LMP1 and LMP2A, and 
results in downregaultion of JMJD1A, which is associated with N stage and poor 
prognosis of NPC patients. 
3. High expression of Syk, which is resulted partly from LMP2A expression in NPC, 
is associated with tumor recurrence and poor prognosis of NPC patients  
4. Downregulation of WNT7A and ITGA9 in NPC is partly due to promoter 
hypermethylation. The potential of WNT7A and ITGA9 as diagnosis or therapeutic 
targets for NPC should be further investigated 
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